Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

The survival benefit of anti-vascular endothelial growth factor (VEGF) therapy in metastatic colorectal cancer (mCRC) patients is limited to a few months because of acquired resistance. We show that anti-VEGF therapy induced remodeling of the extracellular matrix with subsequent alteration of the ph...

Full description

Bibliographic Details
Main Authors: Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., Heishi, T., Martin, J. D., Huang, Y., Maimon, N., Reissfelder, C., Weitz, J., Boucher, Y., Clark, J. W., Duda, D. G., Jain, R. K., Fukumura, D., Ho, William W., Grodzinsky, Alan J
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering
Format: Article
Published: American Association for the Advancement of Science (AAAS) 2018
Online Access:http://hdl.handle.net/1721.1/117742
https://orcid.org/0000-0002-4942-3456

Internet

http://hdl.handle.net/1721.1/117742
https://orcid.org/0000-0002-4942-3456

Similar Items